Also trades as: 0K1R.L (LSE) · $vol 0M
VRDN NASDAQ
Viridian Therapeutics, Inc.
1W: +12.2%
1M: +14.0%
3M: +19.6%
YTD: -23.9%
1Y: +5.8%
3Y: +98.5%
5Y: +40.4%
$24.09
+0.75 (+3.21%)
After Hours: $22.26 (-1.83, -7.60%)
Weekly Expected Move ±9.1%
$18
$20
$22
$24
$26
Credit Risk of going bust: higher than 62% of companies Debt: 8.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.32 (down 99%), Viridian Therapeutics, Inc. would be worth roughly what it owes.
Total debt $242.9M against a stock market value of $2.64B.
Distance to default 4.10 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $121.8M (short-term plus half of long-term), stock volatility 74.2%; Altman Z'' 0.76. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.32 (down 99%), Viridian Therapeutics, Inc. would be worth roughly what it owes.
Total debt $242.9M against a stock market value of $2.64B.
Distance to default 4.10 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $121.8M (short-term plus half of long-term), stock volatility 74.2%; Altman Z'' 0.76. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$20.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.7B
52W Range13.18-34.29
Volume2,808,240
Avg Volume1,962,859
Beta0.96
Dividend—
Analyst Ratings
Company Info
CEOStephen F. Mahoney
Employees252
SectorHealthcare
IndustryBiotechnology
IPO Date2014-06-18
Websiteviridiantherapeutics.com
221 Crescent Street
Waltham, MA 02453
US
Waltham, MA 02453
US
617 272 4600
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Latest News
Viridian Therapeutics presents 54 percent trial data for VRDN stock - ad-hoc-news.de
VRDN261016P00025000 Interactive Stock Chart | VRDN Oct 2026 25.000 put Stock - Yahoo Finance
VRDN261016P00017000 Interactive Stock Chart | VRDN Oct 2026 17.000 put Stock - Yahoo Finance
Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base
Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base - Yahoo Finance
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Tousignant Jennifer | S-Sale | 10,000 | $24.50 | 2026-08-19 |
| Tousignant Jennifer | M-Exempt | 10,000 | $14.41 | 2026-08-19 |
| Tousignant Jennifer | M-Exempt | 10,000 | $14.41 | 2026-08-19 |
| Tripuraneni Radhika | M-Exempt | 40,000 | $13.21 | 2026-08-14 |
| Tripuraneni Radhika | M-Exempt | 40,000 | $13.21 | 2026-08-14 |